Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E70.68 EPS (ttm)2.52 Insider Own0.10% Shs Outstand254.18M Perf Week1.82%
Market Cap45.27B Forward P/E28.85 EPS next Y6.17 Insider Trans-51.74% Shs Float254.18M Perf Month-4.44%
Income655.00M PEG1.49 EPS next Q1.12 Inst Own98.20% Short Float1.66% Perf Quarter-3.18%
Sales3.45B P/S13.11 EPS this Y99.10% Inst Trans0.62% Short Ratio3.66 Perf Half Y-1.88%
Book/sh19.79 P/B9.00 EPS next Y34.75% ROA36.20% Target Price215.84 Perf Year0.86%
Cash/sh15.54 P/C11.46 EPS next 5Y47.38% ROE51.70% 52W Range151.80 - 195.81 Perf YTD7.49%
Dividend- P/FCF32.03 EPS past 5Y23.90% ROI11.20% 52W High-9.03% Beta1.42
Dividend %- Quick Ratio3.60 Sales past 5Y20.30% Gross Margin86.60% 52W Low17.34% ATR4.58
Employees2500 Current Ratio3.70 Sales Q/Q-32.40% Oper. Margin25.50% RSI (14)52.04 Volatility2.46% 2.68%
OptionableYes Debt/Eq0.12 EPS Q/Q-36.10% Profit Margin64.10% Rel Volume1.49 Prev Close176.14
ShortableYes LT Debt/Eq0.11 EarningsOct 30 AMC Payout0.00% Avg Volume1.15M Price178.12
Recom2.00 SMA200.41% SMA500.50% SMA2000.10% Volume1,718,908 Change1.12%
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-01-19Downgrade Needham Buy → Hold
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Sep-20-19 08:31AM  3 Big Biotech Stocks Worth Adding to Your Portfolio Now Zacks
Sep-17-19 10:14AM  The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial Zacks
Sep-16-19 02:25PM  Top Stock Reports for Celgene, Sinopec & HSBC Zacks
Sep-13-19 03:44PM  How Much Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Insiders Taking Off The Table? Simply Wall St.
11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
Sep-12-19 11:43AM  Vertex strikes deal to sell cystic fibrosis drugs in Scotland, but British debate continues American City Business Journals
04:06AM  Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) Business Wire
Sep-11-19 09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Sep-10-19 08:30AM  Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11 Business Wire
Sep-04-19 09:39PM  Dont Blink or Youll Miss Vertexs Next Move, And Its Bound to Be a Good One Motley Fool
06:57PM  Wall Street Green on Wednesday GuruFocus.com
10:32AM  Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M Zacks
10:02AM  Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
08:00AM  Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff Motley Fool
Sep-03-19 09:33AM  Buy Vertex Pharmaceuticals Stock Because of Its Emerging Pipeline Barrons.com
09:15AM  Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M Benzinga
09:06AM  Vertex snaps up Cambridge diabetes startup Semma for $950M American City Business Journals
08:33AM  UPDATE 1-Vertex to buy cell therapy developer Semma for $950 mln Reuters
08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Sep-01-19 09:00AM  3 Healthcare Stocks That Have a Killer Advantage Motley Fool
Aug-31-19 02:37PM  Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More Benzinga
Aug-29-19 05:50PM  Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know Zacks
07:39AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Aug-28-19 01:31PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
10:02AM  Moving Average Crossover Alert: Vertex Pharmaceuticals Zacks
Aug-27-19 08:44AM  3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands InvestorPlace
Aug-26-19 09:30AM  Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year? Zacks
Aug-22-19 11:55AM  The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron Zacks
10:20AM  Check Out These 5 Fast-Growing Stocks to Buy InvestorPlace
07:35AM  Should You Worry About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Salary Level? Simply Wall St.
Aug-21-19 11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
Aug-20-19 07:15PM  Vertex Pharmaceuticals Inc (VRTX) EVP, Global Research and CSO David Altshuler Sold $2. ... GuruFocus.com
12:20PM  Sarepta's FDA rejection could have ripple effect in other Duchenne biotechs American City Business Journals
10:20AM  Surging Earnings Estimates Signal Upside for Vertex (VRTX) Stock Zacks
08:00AM  FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment Business Wire
Aug-14-19 10:53AM  Top Research Reports: Amazon, Caterpillar, Vertex & More Zacks
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
Aug-13-19 10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
Aug-11-19 10:15AM  Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals Motley Fool
Aug-09-19 01:18PM  The 10 Largest-Cap Growth Stocks Motley Fool
10:31AM  Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up Zacks
Aug-08-19 11:06AM  Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up Zacks
10:54AM  Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss Zacks
08:41AM  Is Vertex (VRTX) a Great Growth Stock? Zacks
04:02AM  3 Strong Buy Healthcare Stocks Insiders Are Buying Now TipRanks
Aug-07-19 07:54PM  Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy American City Business Journals
Aug-06-19 09:35PM  Edited Transcript of VRTX earnings conference call or presentation 31-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
07:15PM  Vertex Pharmaceuticals Inc (VRTX) EVPChief Commercial Officer Stuart A Arbuckle Sold $657,132 ... GuruFocus.com
10:04AM  Vertex Has "Significant Financial Firepower" Motley Fool
Aug-05-19 09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Aug-04-19 10:03AM  Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact? Motley Fool
Aug-03-19 01:15AM  Top Biotech Stocks for February 2019 Investopedia
Aug-02-19 10:25AM  Vertex Pharmaceuticals Stock Soared on a Strong Earnings Report Barrons.com
Aug-01-19 04:35PM  US Stocks Deep in the Red on Thursday GuruFocus.com +7.60%
12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
11:23AM  Vertex Pharmaceuticals Inc (VRTX) Q2 2019 Earnings Call Transcript Motley Fool
09:21AM  Proteostasis (PTI) to Post Q2 Earnings: What's in Store? Zacks
Jul-31-19 05:25PM  Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates Zacks
05:07PM  Vertex Posts A Beat-And-Raise As Each Drug Tacks On Growth Investor's Business Daily
04:01PM  Vertex Reports Second-Quarter 2019 Financial Results Business Wire
02:30PM  Vertex Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
12:06PM  Vertex Earnings, Revenue Beat in Q2 Investing.com
Jul-30-19 07:31AM  Why Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Could Be Your Next Investment Simply Wall St.
Jul-29-19 09:15AM  Pfizer Closes in on a Major Spinoff Motley Fool
Jul-26-19 12:04PM  4 Biotech Stocks Sliding Lower InvestorPlace
11:49AM  Vertex (VRTX) to Post Q2 Earnings: What's in the Cards? Zacks
Jul-25-19 11:20AM  Where Will CRISPR Therapeutics Be in 5 Years? Motley Fool
09:32AM  Vertex CEO Jeff Leiden to step down American City Business Journals
08:25AM  Vertex Pharmaceuticals names Chief Medical Officer Reshma Kewalramani as new CEO MarketWatch
08:00AM  Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer Business Wire
Jul-24-19 10:58AM  Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded Zacks
10:33AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-23-19 05:03PM  Is Vertex Pharmaceuticals a Buy? Motley Fool
02:47PM  5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
03:03AM  3 Perfect 10 Biotech Stocks to Buy TipRanks
Jul-22-19 07:28PM  8 Health-Care Stocks for Your Portfolio Kiplinger
08:00AM  Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis Business Wire
Jul-18-19 01:33PM  Top Stock Reports for Johnson & Johnson, NextEra & Deere Zacks
09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
09:00AM  2 Supercharged Growth Stocks I'd Buy Right Now Motley Fool
Jul-17-19 10:32AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
09:00AM  Vertex to Announce Second-Quarter 2019 Financial Results on July 31 Business Wire
Jul-16-19 06:05PM  Should You Pick Up Novartis (NVS) Before Q2 Earnings? Zacks
10:07AM  Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA Zacks
Jul-14-19 07:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2019 Motley Fool
Jul-13-19 07:26AM  Health care is one of the stock markets healthiest sectors right now MarketWatch
Jul-12-19 08:23AM  3 Big Stock Charts for Friday: HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals InvestorPlace
Jul-10-19 08:16AM  Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June Motley Fool
Jul-09-19 03:55PM  Federal judge blocks Trump Administration's proposal to include wholesale drug prices in TV ads Yahoo Finance Video
Jul-04-19 07:49AM  Here's Why I Think Vertex Pharmaceuticals (NASDAQ:VRTX) Might Deserve Your Attention Today Simply Wall St.
Jul-03-19 01:49PM  Why These 4 Biotech Leaders Could Rebound On Strong Earnings Investor's Business Daily
Jul-01-19 11:12PM  How to Invest in Biotech Stocks Motley Fool
Jun-29-19 04:35PM  3 Growth Stocks to Buy and Hold for the Next 50 Years Motley Fool
08:25AM  The Week Ahead In Biotech: Pending Clinical Readouts In Focus Benzinga
Jun-26-19 08:37AM  Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More Zacks
Jun-25-19 11:02AM  The 10 Biggest Biotech Stocks Motley Fool
Jun-24-19 11:00PM  Playing with tech to create drug-free ADHD treatment Financial Times
10:05AM  Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children Zacks
Jun-22-19 08:00AM  3 Stocks That Could Double Your Money Motley Fool
Jun-21-19 02:30PM  FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene Business Wire
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Option Exercise103.2512,5011,290,68136,212Aug 20 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Sale186.3812,5012,329,97631,553Aug 20 04:30 PM
MCGLYNN MARGARET GDirectorAug 13Option Exercise81.5410,000815,40014,124Aug 15 04:11 PM
MCGLYNN MARGARET GDirectorAug 13Sale185.0010,0001,850,0004,124Aug 15 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Option Exercise131.892,125280,26635,365Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Sale181.892,125386,51633,240Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Option Exercise86.521,553134,36633,793Aug 06 04:41 PM
Parini MichaelEVP, CL&AOAug 05Option Exercise86.522,330201,59237,333Aug 06 04:43 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Sale176.441,553274,01132,240Aug 06 04:41 PM
Parini MichaelEVP, CL&AOAug 05Sale175.282,330408,39935,003Aug 06 04:43 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise91.052,155196,21334,395Aug 06 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale177.782,155383,11632,240Aug 06 04:41 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86637,128Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 12Sale175.272,125372,45535,003Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41339,253Jul 09 04:49 PM
Parini MichaelEVP, CL&AOJul 05Sale179.114,250761,23935,003Jul 09 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Option Exercise131.892,125280,26635,365Jun 20 04:53 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Sale181.892,125386,51633,240Jun 20 04:53 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Option Exercise77.3156,0304,331,679162,317Jun 20 04:43 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Sale175.3956,0309,827,054106,287Jun 20 04:43 PM
Bhatia Sangeeta N.DirectorJun 03Sale167.08720120,2986,540Jun 04 04:08 PM
Parini MichaelEVP, CL&AOMay 30Sale173.00707122,31135,625May 06 04:08 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Option Exercise77.31113,4328,769,428219,719May 28 05:45 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Sale175.10113,43219,861,943106,287May 28 05:45 PM
Sachdev AmitEVP, CROMay 15Sale165.416110,09033,416May 17 04:37 PM
Silva Paul MSVP & ControllerMay 15Sale165.4116126,63117,759May 17 04:31 PM
Parini MichaelEVP, CL&AOMay 15Sale165.418313,72935,003May 17 04:29 PM
Kewalramani ReshmaEVP and CMOMay 15Sale165.4124139,86413,736May 17 04:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale165.4113322,00033,240May 17 04:18 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale165.419115,05231,553May 17 04:16 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Option Exercise77.3133,0582,555,714136,953May 08 04:10 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Sale175.0133,0585,785,504106,195May 08 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Option Exercise86.521,553134,36634,793May 06 04:06 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,329201,50537,332May 06 04:08 PM
Parini MichaelEVP, CL&AOMay 03Sale172.061,622279,07435,003May 06 04:08 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Sale172.391,553267,72333,240May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Option Exercise91.052,155196,21335,395May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Sale169.272,155364,76833,240May 06 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Option Exercise77.3110,480810,209116,375May 03 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Sale175.0810,4801,834,826106,195May 03 04:06 PM
Parini MichaelEVP, CL&AOApr 16Option Exercise111.736,375712,27939,253Apr 18 04:12 PM
Parini MichaelEVP, CL&AOApr 16Sale181.996,3751,160,16635,003Apr 18 04:12 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 15Sale181.755,6241,022,14833,240Apr 17 04:30 PM
LEIDEN JEFFREY MCEO & PresidentFeb 19Sale186.9820,9973,926,113106,195Feb 21 04:24 PM
Kewalramani ReshmaEVP and CMOFeb 19Sale186.941,488278,16313,736Feb 21 04:22 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 19Sale187.005,6241,051,71631,553Feb 21 04:21 PM
Silva Paul MSVP & Interim CFOFeb 19Sale186.972,812525,74717,759Feb 21 04:27 PM
Parini MichaelEVP, CL&AOFeb 19Sale186.985,6241,051,58535,003Feb 21 04:26 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale180.24111,43120,083,804127,192Feb 13 04:39 PM
Sachdev AmitEVP, CROFeb 11Sale180.0635,0956,319,21640,165Feb 13 04:40 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale180.2232,9565,939,18837,177Feb 13 04:36 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 11Sale180.2133,0735,959,96938,864Feb 13 04:37 PM
Silva Paul MSVP & Interim CFOFeb 11Sale180.164,215759,36720,571Feb 13 04:27 PM
Silva Paul MSVP & Interim CFOFeb 06Option Exercise91.051,289117,36313,938Feb 07 04:04 PM
Silva Paul MSVP & Interim CFOFeb 06Sale193.001,289248,77712,649Feb 07 04:04 PM
Parini MichaelEVP, CL&AOFeb 04Option Exercise86.522,330201,59238,489Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Option Exercise88.494,126365,11741,443Feb 06 04:46 PM
Silva Paul MSVP & Interim CFOFeb 04Option Exercise86.5280969,99516,896Feb 06 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Option Exercise99.977,959795,65754,711Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Option Exercise88.904,097364,23548,817Feb 06 04:51 PM
Sachdev AmitEVP, CROFeb 04Sale186.8612,7222,377,29638,037Feb 06 04:51 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Sale186.2018,3093,409,08236,402Feb 06 04:50 PM
Silva Paul MSVP & Interim CFOFeb 04Sale187.024,247794,27312,649Feb 06 04:49 PM
LEIDEN JEFFREY MCEO & PresidentFeb 04Sale186.3532,2506,009,682124,865Feb 06 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Sale189.194,126780,59839,113Feb 06 04:46 PM
Parini MichaelEVP, CL&AOFeb 04Sale189.192,330440,81336,159Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Option Exercise131.892,125280,26641,238Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Option Exercise131.892,125280,26648,877Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Option Exercise155.573,668570,63143,277Jan 24 04:47 PM
Parini MichaelEVP, CL&AOJan 22Sale195.003,668715,26039,609Jan 24 04:47 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Sale193.482,125411,14546,752Jan 24 04:46 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Sale193.482,125411,14539,113Jan 24 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Option Exercise155.701,223190,42140,336Jan 22 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Sale194.621,223238,02039,113Jan 22 04:07 PM
Silva Paul MSVP & Corp ControllerJan 17Option Exercise90.623,007272,48217,376Jan 18 04:18 PM
Silva Paul MSVP & Corp ControllerJan 17Sale190.623,007573,18216,087Jan 18 04:18 PM
Parini MichaelEVP, CL&AOJan 14Option Exercise90.292,125191,86641,734Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 14Sale186.712,125396,75939,609Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 04Option Exercise122.454,250520,41343,859Jan 07 04:02 PM
Parini MichaelEVP, CL&AOJan 04Sale165.904,250705,07539,609Jan 07 04:02 PM
SACHS BRUCE IDirectorDec 06Option Exercise34.2410,000342,40023,011Dec 07 04:06 PM
Silva Paul MSVP & Corp ControllerDec 03Option Exercise86.5280969,99516,896Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerDec 03Sale186.52809150,89516,087Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerNov 15Sale163.75121,96516,087Nov 19 05:52 PM
Parini MichaelEVP, CL&AONov 15Sale163.759014,73839,609Nov 19 05:47 PM
Sachdev AmitEVP, CRONov 15Sale163.75619,98946,662Nov 19 05:34 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale163.75294,74946,752Nov 19 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale163.7510016,37539,113Nov 19 05:23 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Option Exercise86.522,330201,59241,443Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Option Exercise103.095,803598,21151,002Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Option Exercise86.522,330201,59241,939Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Option Exercise86.521,941167,93548,603Nov 06 04:45 PM
Sachdev AmitEVP, CRONov 05Sale173.731,941337,20446,662Nov 06 04:45 PM
Parini MichaelEVP, CL&AONov 05Sale172.082,330400,94639,609Nov 06 04:32 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Sale172.085,803998,58046,752Nov 06 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Sale172.082,330400,94639,113Nov 06 04:11 PM